Please login to the form below

Not currently logged in
Email:
Password:

BMS' Yervoy picks up another indication in Europe

The EC licenses the immuno-oncology treatment for children with skin cancer

BMSBMS has chalked up a strong win this week, with its immuno-oncology treatment Yervoy (ipilimumab) becoming the first and only agent to receive EU approval to treat paediatric patients with skin cancer.

More specifically, Yervoy is now approved to treat patients 12 years and older for metastatic or unresectable melanoma, expanding its indications following an initial approval as an adjuvant treatment for patients with cutaneous melanoma.

The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck & Co’s Keytruda (pembrolizumab), which was found to be more effective than Yervoy with patients reporting a better PFS with fewer side effects.

Commenting on the drug’s new indication Fouad Namouni, head of development, oncology at Bristol Myers Squibb, said: “The expanded EU indication of Yervoy for paediatric patients with unresectable or metastatic melanoma is an outcome of BMS’s unyielding commitment to advancing treatments for patients with unmet clinical needs.

“With this approval, we’re able to provide an alternative to young patients whose treatment options have traditionally been limited.”

Yervoy gained its approval on the back of two clinical trials, with data showing the overall safety profile for children and adolescents of Yervoy was consistent with that for adults.

The European approval follows a decision by the US Food and Drug Administration’s (FDA) to approve the drug for the same indication back in July last year.

However, Merck & Co’s leading position in the cancer immunotherapies market is so far unmatched, with Keytruda picking up more indications, most recently in lung cancer. Analysts have suggested that Keytruda’s recent data in that indication will ‘solidify’ Merck’s lead in first-line NSCLC.

Article by
Gemma Jones

23rd January 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics